Stifel Downgrades Fulcrum Therapeutics (FULC) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Cantor Fitzgerald Downgrades Fulcrum Therapeutics (FULC) to Neutral
September 12, 2024 8:50 AM EDTCantor Fitzgerald analyst Kristen Kluska downgraded Fulcrum Therapeutics (NASDAQ: FULC) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Fulcrum Therapeutics click here. For more ratings news on Fulcrum Therapeutics click here.
Shares of Fulcrum Therapeutics closed at $8.85 yesterday.
... MoreFulcrum Therapeutics (FULC) Reports Topline Results from Phase 3 REACH Trial of Losmapimod
September 12, 2024 6:55 AM EDTFulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced that its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo. In addition, secondary endpoints did not achieve nominal statistical significance. The safety and tolerability profile of losmapimod was consistent with previously reported studies. The Company will complete a full evaluation of the data it received this week and plans to share the results at an upcoming medical meeting.
We are deeply disappointed that the REACH trial did not... More
